AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37142388 — intervention group
Group type: COMPARATOR
Intervention: Low oxygenation (85-89% SpO2)
Number of subjects: 20
Study 37142418 — intervention group
Group type: EXPERIMENTAL
Intervention: CoolSource cooling vest
Number of subjects: 30
Study 37142474 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily opioid dose in morphine milligram equivalents (MME)
Number of subjects: 1421
Study 37142474 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of distinct prescribers visited
Number of subjects: 1421
Study 37142474 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of distinct pharmacies visited
Number of subjects: 1421
Study 37142543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (standard treatment)
Number of subjects: 0
Study 37142543 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene addition therapy
Number of subjects: 0
Study 37142543 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome editing using CRISPR-Cas9 nuclease
Number of subjects: 0
Study 37142543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell generation from induced pluripotent stem cells
Number of subjects: 0
Study 37142543 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA therapeutics
Number of subjects: 0
Study 37142551 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO 2015 definition for RSV-LRTI
Number of subjects: 2401
Study 37142551 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative case definitions for RSV-LRTI
Number of subjects: 2401
Study 37142551 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO 2015 definition for severe RSV-LRTI
Number of subjects: 2401
Study 37142551 — intervention group
Group type: COMPARATOR
Intervention: LRTI/bronchiolitis/pneumonia cases clinically diagnosed by nonstudy physicians
Number of subjects: 2401
Study 37142730 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based treatment (n=99)
Number of subjects: 139
Study 37142730 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 139
Study 37142733 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose antibiotic (IIIrd gen cephalosporin) administered within 30-min of POEM
Number of subjects: 114
Study 37142733 — intervention group
Group type: COMPARATOR
Intervention: Multiple dose antibiotic (IIIrd gen cephalosporin) administered for a total of three days
Number of subjects: 114
Study 37142733 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose antibiotic (IIIrd gen cephalosporin)
Number of subjects: 114
Study 37142733 — intervention group
Group type: COMPARATOR
Intervention: Multiple dose antibiotic (IIIrd gen cephalosporin)
Number of subjects: 114
Study 37142763 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311
Study 37142763 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311
Study 37142763 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab
Number of subjects: 311
Study 37142763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 37142762 — intervention group
Group type: EXPERIMENTAL
Intervention: Banff Automation System
Number of subjects: 3054
Study 37142988 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water drinking
Number of subjects: 29584
Study 37142988 — intervention group
Group type: COMPARATOR
Intervention: Control (non-tap water drinking)
Number of subjects: 29584
Study 37143003 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Forensic Outpatient Systemic Therapy (FASTb)
Number of subjects: 200
Study 37143003 — intervention group
Group type: COMPARATOR
Intervention: Regular Forensic Outpatient Systemic Therapy (FASTr)
Number of subjects: 200
Study 37143003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FASTb and FASTr
Number of subjects: 200
Study 37143029 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HBV screening
Number of subjects: 0
Study 37143040 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day)
Number of subjects: 86
Study 37143072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention based on temporal patterns of falls
Number of subjects: 0
Study 37143072 — intervention group
Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 0
Study 37143072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 0
Study 37143108 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived organoids and in-vitro sensitivity testing
Number of subjects: 90
Study 37143128 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI)
Number of subjects: 480
Study 37143128 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI combined with mood stabilizer
Number of subjects: 480
Study 37143128 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI combined with quetiapine (≥ 150 mg/day)
Number of subjects: 480
Study 37143128 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 480
Study 37143128 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up until 4 years or switching to BD
Number of subjects: 480
Study 37143131 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Readiness to Change Assessment (ORCA) tool - context domain
Number of subjects: 59
Study 37143131 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Readiness to Change Assessment (ORCA) tool - facility resources
Number of subjects: 59
Study 37143154 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy, conventionally fractioned RT with isotoxic dose escalation up to 70 Gy, online plan adaptation performed once weekly or in case of major anatomical changes.
Number of subjects: 30
Study 37143154 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy.
Number of subjects: 30
Study 37143158 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) followed by surgery within 24 hours
Number of subjects: 100
Study 37143158 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (surgery followed by conventional radiotherapy after 1-2 weeks)
Number of subjects: 100
Study 37143199 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0
Study 37143408 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy competencies for management of nociplastic pain
Number of subjects: 23
Study 37143685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus simvastatin (5 mg BID for 7 days followed by 10 mg BID for 7 days and 40 mg once a day for 14 days)
Number of subjects: 92
Study 37143685 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 92
Study 37143685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiling
Number of subjects: 92
Study 37143685 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Machine Learning analysis
Number of subjects: 92
Study 37143955 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyaderm®
Number of subjects: 66
Study 37143955 — intervention group
Group type: COMPARATOR
Intervention: STSG
Number of subjects: 66
Study 37143998 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP infusion for 20 min
Number of subjects: 0
Study 37143998 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP infusion for 20 min
Number of subjects: 0
Study 37143999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial TNK (4 mg) followed by TNK (0.4 mg/min for 20 min) during EVT
Number of subjects: 26
Study 37143999 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical cohort)
Number of subjects: 26
Study 37144003 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (individual and group sessions over a 6-weeks period)
Number of subjects: 120
Study 37144109 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3708
Study 37144109 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 3708
Study 37144150 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 100
Study 37144150 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming phase post-therapeutic hypothermia
Number of subjects: 100
Study 37144150 — intervention group
Group type: COMPARATOR
Intervention: Neonatal controls (no hypothermia)
Number of subjects: 100
Study 37144153 — intervention group
Group type: EXPERIMENTAL
Intervention: Own Mother's Milk (OMM)
Number of subjects: 0
Study 37144153 — intervention group
Group type: COMPARATOR
Intervention: Donor Human Milk (DHM)
Number of subjects: 0
Study 37144470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound levels measured continuously using a Gravity Sound Level Meter.
Number of subjects: 136
Study 37144470 — intervention group
Group type: EXPERIMENTAL
Intervention: Light levels measured continuously using an Adafruit TSL2561 digital luminosity sensor.
Number of subjects: 136
Study 37144470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound and light monitoring across different times of the day.
Number of subjects: 136
Study 37144470 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of sound and light events during weekdays and weekends.
Number of subjects: 136
Study 37144470 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of alarm frequencies in the ICU.
Number of subjects: 136
Study 37144478 — intervention group
Group type: EXPERIMENTAL
Intervention: Women’s suggestions on improving maternal and newborn care during facility-based birth in Italy during the COVID-19 pandemic.
Number of subjects: 2010
Study 37144478 — intervention group
Group type: EXPERIMENTAL
Intervention: Word co-occurrence network (WCON) analysis of women's responses.
Number of subjects: 2010
Study 37144634 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.14 g·kg -1 ·d -1)
Number of subjects: 237
Study 37144678 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained surgeons
Number of subjects: 8
Study 37144678 — intervention group
Group type: COMPARATOR
Intervention: Self-taught surgeons
Number of subjects: 8
Study 37144820 — intervention group
Group type: EXPERIMENTAL
Intervention: CushMed (16 patients treated with stable cortisol-lowering drug dosage)
Number of subjects: 44
Study 37144820 — intervention group
Group type: COMPARATOR
Intervention: CushSurg (13 patients cured by pituitary surgery)
Number of subjects: 44
Study 37144820 — intervention group
Group type: EXPERIMENTAL
Intervention: CushBla (15 patients receiving hydrocortisone after bilateral adrenalectomy)
Number of subjects: 44
Study 37144820 — intervention group
Group type: EXPERIMENTAL
Intervention: CushMed (16 patients)
Number of subjects: 44
Study 37145134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG/Er:YAG dual laser therapy (4 treatments, 1-2 months apart)
Number of subjects: 66
Study 37145134 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid application (6 months)
Number of subjects: 66
Study 37145134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG/Er:YAG dual laser therapy
Number of subjects: 66
Study 37145134 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG/Er:YAG dual laser therapy and Topical steroid application
Number of subjects: 66
Study 37145169 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 0
Study 37145169 — intervention group
Group type: EXPERIMENTAL
Intervention: paxalisib
Number of subjects: 0
Study 37145169 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 and paxalisib (combination)
Number of subjects: 0
Study 37145174 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic management (EG)
Number of subjects: 78
Study 37145174 — intervention group
Group type: COMPARATOR
Intervention: Surgical management (SG)
Number of subjects: 78
Study 37145268 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated fall risk assessment tool (KaatumisSeula® [KS])
Number of subjects: 384
Study 37145600 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, individualized, and goal-oriented rehabilitation program (8 sessions over 4 months)
Number of subjects: 120
Study 37145600 — intervention group
Group type: COMPARATOR
Intervention: Usual care in municipality
Number of subjects: 120
Study 37145975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib co-administered with rifabutin
Number of subjects: 13
Study 37145975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 13
Study 37146180 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake of 235 (133, 401) μg/day
Number of subjects: 29
Study 37146180 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake >400 μg/day
Number of subjects: 29
Study 37146180 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term iodine intake >400 μg/day
Number of subjects: 29
Study 37146219 — intervention group
Group type: COMPARATOR
Intervention: Parenting interventions
Number of subjects: 1925
Study 37146219 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 1925
Study 37146219 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial empowerment programme
Number of subjects: 1925
Study 37146227 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab + axitinib (PEM+AXI)
Number of subjects: 15177
Study 37146227 — intervention group
Group type: EXPERIMENTAL
Intervention: nivolumab + ipilimumab (NIV+IPI)
Number of subjects: 15177
Study 37146227 — intervention group
Group type: EXPERIMENTAL
Intervention: lenvatinib + pembrolizumab (LEN+PEM)
Number of subjects: 15177
Study 37146227 — intervention group
Group type: EXPERIMENTAL
Intervention: pazopanib (PAZ)
Number of subjects: 15177
Study 37146227 — intervention group
Group type: EXPERIMENTAL
Intervention: cabozantinib (CAB)
Number of subjects: 15177
Study 37146263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerable participants with MDS
Number of subjects: 449
Study 37146263 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS patients with low, intermediate, and high-risk disease
Number of subjects: 449
Study 37146263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerable MDS participants
Number of subjects: 449
Study 37146263 — intervention group
Group type: COMPARATOR
Intervention: Overall HRQoL among patients with cytopenias
Number of subjects: 449
Study 37146263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerability vs disease risk in MDS
Number of subjects: 449
Study 37146444 — intervention group
Group type: EXPERIMENTAL
Intervention: StayWell text messaging intervention (60-day program based on cognitive behavioral therapy)
Number of subjects: 398
Study 37146530 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercises
Number of subjects: 52
Study 37146752 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg plus tremelimumab 1 mg/kg administered intravenously every 4 weeks for four doses, followed by up to nine doses of durvalumab monotherapy every 4 weeks for up to 12 months or until disease progression
Number of subjects: 78
Study 37146752 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 78
Study 37146761 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of dietary micronutrient adequacy (85.8%-97.7%)
Number of subjects: 1461
Study 37146761 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of dietary micronutrient adequacy (40.1%-78.7%)
Number of subjects: 1461
Study 37146761 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-SD increment in minerals and vitamins adequacy
Number of subjects: 1461
Study 37146874 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral therapy (ABBT) plus treatment-as-usual (TAU)
Number of subjects: 240
Study 37146874 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) only
Number of subjects: 240
Study 37147083 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV) administration
Number of subjects: 60
Study 37147083 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable biosensors monitoring
Number of subjects: 60
Study 37147083 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms
Number of subjects: 60
Study 37147124 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term air pollution exposure (specifically nitrogen dioxide - NO2)
Number of subjects: 449
Study 37147201 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-antigen vaccine (PreHevbrio™)
Number of subjects: 100000
Study 37147201 — intervention group
Group type: COMPARATOR
Intervention: Single-antigen vaccine (Engerix-B)
Number of subjects: 100000
Study 37147298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 41
Study 37147298 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial circulating tumor DNA sampling
Number of subjects: 41
Study 37147301 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin added to intensive chemotherapy in late group (2016-2020)
Number of subjects: 227
Study 37147301 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin in NPM1 mutated patients (n=151)
Number of subjects: 227
Study 37147301 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin in low and high FLT3-ITD allelic ratio patients
Number of subjects: 227
Study 37147301 — intervention group
Group type: COMPARATOR
Intervention: Control group (naive patients)
Number of subjects: 227
Study 37147301 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin in late group (2016-2020)
Number of subjects: 227
Study 37147320 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down position (HDP) -20° Trendelenburg
Number of subjects: 96
Study 37147320 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 96
Study 37147462 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote digital postoperative wound monitoring for 30-days postoperatively
Number of subjects: 200
Study 37147462 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote digital postoperative wound monitoring
Number of subjects: 200
Study 37147496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 3
Study 37147587 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving Well intervention (peer coach behavioral intervention)
Number of subjects: 0
Study 37147587 — intervention group
Group type: COMPARATOR
Intervention: Staying Well (attention control group)
Number of subjects: 0
Study 37147635 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain severity (NRS score)
Number of subjects: 1179
Study 37147635 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline pain
Number of subjects: 1179
Study 37147635 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline frailty
Number of subjects: 1179
Study 37147635 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants transitioning to frailty over one year
Number of subjects: 1179
Study 37147638 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement control exercise with specific breathing techniques (SBTs)
Number of subjects: 30
Study 37147638 — intervention group
Group type: COMPARATOR
Intervention: Movement control exercise without specific breathing techniques (SBTs)
Number of subjects: 30
Study 37147642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dronabinol (BX-1) once daily before bedtime for 10 weeks
Number of subjects: 0
Study 37147642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37147642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dronabinol (BX-1)
Number of subjects: 0
Study 37147645 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 1999
Study 37147667 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral treatment (ICBT)
Number of subjects: 4
Study 37147690 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT II) in low-NED subgroup (n=56)
Number of subjects: 321
Study 37147690 — intervention group
Group type: COMPARATOR
Intervention: Placebo in low-NED subgroup (n=48)
Number of subjects: 321
Study 37147690 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT II) in high-NED subgroup (n=107)
Number of subjects: 321
Study 37147690 — intervention group
Group type: COMPARATOR
Intervention: Placebo in high-NED subgroup (n=110)
Number of subjects: 321
Study 37147708 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants experiencing sexual violence
Number of subjects: 1384
Study 37147708 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants experiencing physical violence 5 times or more in < 6 months
Number of subjects: 1384
Study 37147708 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants using illicit drugs in the last month
Number of subjects: 1384
Study 37147708 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants reporting higher levels of internalized stigma
Number of subjects: 1384
Study 37147708 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in the absence of the SAVA syndemic factors
Number of subjects: 1384
Study 37147708 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVA syndemic factors (substance use and violence) among non-depressed FSW
Number of subjects: 1384
Study 37147708 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint experience of depression and SAVA syndemics
Number of subjects: 1384
Study 37147725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid outreach following unsuppressed virus
Number of subjects: 512
Study 37147725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid outreach following missed pharmacy refill collection
Number of subjects: 512
Study 37147725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid outreach following missed doses as detected by an electronic adherence monitoring device
Number of subjects: 512
Study 37147725 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly check-in texts
Number of subjects: 512
Study 37147725 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced peer support
Number of subjects: 512